Research programme: antibacterials/antifungals - Cetek/IntraBiotics
Latest Information Update: 21 Apr 2004
At a glance
- Originator Ardea Biosciences; Cetek Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Mycoses
Most Recent Events
- 21 Apr 2004 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 21 Apr 2004 Discontinued - Preclinical for Mycoses in USA (unspecified route)
- 17 Apr 2001 Preclinical development for Bacterial infections in USA (Unknown route)